-
Mashup Score: 12Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells - Nature Cancer - 2 year(s) ago
Zhai et al. identify clinical brain-penetrant BACE1 inhibitors as regulators of macrophage-dependent phagocytosis in glioblastoma through IL-6–STAT3 signaling and demonstrate preclinical therapeutic efficacy in orthotopic mouse models and PDXs.
Source: Nature CancerCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 13NR2F2 controls malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation - Nature Cancer - 2 year(s) ago
Blanpain and colleagues identify NR2F2 as a regulator of stemness and invasiveness that promotes tumor renewal and restricts differentiation to sustain squamous cell carcinomas.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The nuclear receptor NR2F2 as uniquely expressed in malignant skin SCC and promotes cancer stem cell properties https://t.co/U3bCwGc48D
-
-
Mashup Score: 1Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells - Nature Cancer - 2 year(s) ago
Zhai et al. identify clinical brain-penetrant BACE1 inhibitors as regulators of macrophage-dependent phagocytosis in glioblastoma through IL-6–STAT3 signaling and demonstrate preclinical therapeutic efficacy in orthotopic mouse models and PDXs.
Source: Nature CancerCategories: Latest Headlines, Oncologists2Tweet-
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells | Nature Cancer https://t.co/FWxWhHNbs2
-
-
Mashup Score: 15
Lehtiö and colleagues perform proteogenomic analysis of non-small cell lung cancer and identify molecular subtypes with distinct immune-evasion mechanisms and therapeutic targets and validate their classification method in separate clinical cohorts.
Source: Nature CancerCategories: Latest Headlines, Oncologists2Tweet-
🆕@NatureCancer🔥 Identified 6 distinct #lungcancer proteome subtypes w/ striking differences in immune cell composition & subtype-spec expression of immune checkpoints suggesting potential clinical value for tailored treatm stratification #LCSM 👏Amazing https://t.co/gmvdfb5ttm https://t.co/xoFwXGdtIs
-
-
Mashup Score: 1
Lehtiö and colleagues perform proteogenomic analysis of non-small cell lung cancer and identify molecular subtypes with distinct immune-evasion mechanisms and therapeutic targets and validate their classification method in separate clinical cohorts.
Source: Nature CancerCategories: Latest Headlines, Oncologists1Tweet-
Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms | Nature Cancer https://t.co/NUgNLcSKF3
-
-
Mashup Score: 6A key malignant switch in skin SCC - Nature Cancer - 3 year(s) ago
The mechanisms regulating the progression of benign tumors to malignant carcinomas remain incompletely understood. A new study identifies the transcription factor NR2F2 as a specific regulator of this transition that plays critical roles in the maintenance of the malignant tumor state.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @alexia_zz: And don't miss the News & Views by #NickBarker @astar_research: 👇🏻 https://t.co/ZwXo1i6adK https://t.co/R4pvsgwZE8
-
-
Mashup Score: 11
Sarry and colleagues demonstrate that adaptive resistance to venetoclax + cytarabine therapy in acute myeloid leukemia relies on mitochondrial respiration and show that combination with electron transport chain complex inhibitors delays relapse in patient-derived xenograft models in vivo.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Primary AML cells resistant to cytarabine and with a high MitoScore (i.e. high mitochondria oxidative phosphorylation) rely on mitochondrial Bcl2 and are highly sensitive to venetoclax + cytarabine but not to venetoclax + azacytidine: https://t.co/NXSe8B9PUJ #leusm
-
-
Mashup Score: 1The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer - Nature Cancer - 3 year(s) ago
Durocher and colleagues identify CIP2A through synthetic lethal CRISPR screens as a key regulator of adaptive feedback mechanisms controlling chromosomal stability arising from accumulated DNA lesions in BRCA-mutated tumor cells.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
CRISPR screens in cell line models revealed that loss of the protein phosphatase CIP2A is synthetic lethal with BRCA1/2 deficiency, with the CIP2A–TOPBP1 axis safeguarding chromosome stability: https://t.co/r1fj0aPQBe
-
-
Mashup Score: 9TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer - Nature Cancer - 3 year(s) ago
Singh and colleagues show that PDAC phenotypic plasticity is regulated via AP1 enhancer remodeling and modulated by TNF-α+ macrophages and pharmacological inhibition of the BRD4–cJUN–CCL2–TNF-α axis restores favorable PDAC subtypes and prognosis.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
BRD4-driven cJUN/AP1 expression in PDACs results in CCL2-mediated recruitment of TNF-producing macrophages, which force classical (JUNB/AP1) neoplastic cells into an aggressive basal-like state; BRD4 inhibition restores the classical identity: https://t.co/r8nScPkSyX #PancSM
-
-
Mashup Score: 12TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer - Nature Cancer - 3 year(s) ago
Singh and colleagues show that PDAC phenotypic plasticity is regulated via AP1 enhancer remodeling and modulated by TNF-α+ macrophages and pharmacological inhibition of the BRD4–cJUN–CCL2–TNF-α axis restores favorable PDAC subtypes and prognosis.
Source: Nature CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
⭐️ONLINE NOW @NatureCancer: "TNF-α-producing #macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer", a *FAB* work by @ShivKSingh6 Don't miss it! 👇👇 https://t.co/db2LblzlR7 https://t.co/YU78EE2eIM #WorldPancreaticCancerDay https://t.co/IMSm95AG25
-
“Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells” by Shideng Bao et al. Nature Cancer https://t.co/81bM8NmnLP